Relay Therapeutics, Inc.
RLAY
$12.78
-$0.44-3.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 39.04% | 53.45% | -16.49% | -76.27% | -78.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.04% | 53.45% | -16.49% | -76.27% | -78.26% |
| Cost of Revenue | -16.49% | -17.73% | -17.63% | -16.20% | -5.86% |
| Gross Profit | 17.91% | 20.06% | 17.67% | 9.02% | -2.94% |
| SG&A Expenses | -35.75% | -26.99% | -18.16% | -7.65% | 0.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.44% | -19.61% | -17.74% | -14.55% | -4.63% |
| Operating Income | 21.64% | 21.50% | 17.77% | 8.73% | -2.41% |
| Income Before Tax | 18.20% | 18.13% | 13.79% | 3.49% | -1.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.20% | 18.13% | 13.79% | 3.49% | -1.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.20% | 18.13% | 13.79% | 3.49% | -1.30% |
| EBIT | 21.64% | 21.50% | 17.77% | 8.73% | -2.41% |
| EBITDA | 21.30% | 21.31% | 17.71% | 8.70% | -2.50% |
| EPS Basic | 29.89% | 32.76% | 33.03% | 22.77% | 15.40% |
| Normalized Basic EPS | 32.49% | 35.45% | 36.37% | 26.95% | 14.06% |
| EPS Diluted | 29.89% | 32.76% | 33.03% | 22.77% | 15.40% |
| Normalized Diluted EPS | 32.49% | 35.45% | 36.37% | 26.95% | 14.06% |
| Average Basic Shares Outstanding | 14.32% | 20.14% | 28.67% | 26.91% | 22.04% |
| Average Diluted Shares Outstanding | 14.32% | 20.14% | 28.67% | 26.91% | 22.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |